While some people with recent-onset axial spondyloarthritis whose joint damage isn’t visible on an X-ray will progress within 10 years to ankylosing spondylitis (AS), where joint damage becomes evident on an X-ray, the risk is relatively low, a French study found. The risk was about halved in patients on TNF inhibitors, but more…

The decision to escalate treatment for people with highly active axial spondyloarthritis (axSpA) is mainly driven by the physician’s perspective on disease activity, a real-world study has revealed. Further research is needed to better understand these decisions and to optimize axSpA management, according to researchers in the study “…

An experimental therapy called LNK01001 can safely lower a measure of inflammation, pain, and stiffness in adults with active ankylosing spondylitis (AS) who were refractory or intolerant to non-steroidal anti-inflammatory drugs. These top-line data from a 12-week Phase 2 clinical trial support moving LNK01001 to a Phase 3 trial,…

High levels of the pro-inflammatory molecule GM-CSF were found in the bloodstream of people with active ankylosing spondylitis (AS) and strongly correlated with disease activity, a pilot study suggested. Despite helping to lower disease activity, anti-TNF therapies did not affect GM-SCF levels. As such, GM-SCF may represent a…

AbbVie’s Rinvoq (upadacitinib) has been recommended for approval in the European Union as a treatment for active ankylosing spondylitis (AS) in adults. The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, also supports Rinvoq’s approval to treat adults with active psoriatic…

AbbVie has submitted an application to the U.S. Food and Drug Administration (FDA) requesting the approval of Rinvoq (upadacitinib) for the treatment of adults with active ankylosing spondylitis (AS). A separate application was submitted to the European Medicines Agency (EMA) by AbbVie earlier this year,…

The U.S. Food and Drug Administration (FDA) has approved a label update to Novartis’ Cosentyx (secukinumab), doubling the previously recommended dose to 300 mg for adults with active ankylosing spondylitis (AS). “This approval gives clinicians added flexibility to ensure patients are able to achieve the best…

Eli Lilly‘s Taltz (ixekizumab) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with active ankylosing spondylitis (AS), also known as radiographic axial spondyloarthritis. Taltz is a biological therapy, or a biological disease-modifying antirheumatic drug (bDMARD), that blocks…